Ultime notizie per Transcat (NASDAQ:TRNS) Azioni

Transcat

Transcat Inc is involved in providing calibration and laboratory instrument services and distribution of test, measurement, and control instrumentation. Its product and services portfolio consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, etc. The firm has Service and Distribution operating segments. It derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Estech, FLIR, Fluke, Keysight, and Megger among others. It serves to pharmaceutical, industrial manufacturing, energy, and chemical process industries.

Transcat Inc

WIIM

CTOS

DNOW

DSGR

HEES

TITN

TRNS

XMTR

Shares of industrial distribution companies are trading higher. Investors may be weighing the potential impact of Donald Trump's policies on the sector.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays cut Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) price target from $120 to $90. Barclays analyst Tom O&#8217;Malley maintained an Equal-Weight rating. Qorvo shares closed at $100.48 on Tuesday. See how other analysts view this stock.</li>
<li>B of A Securities raised the price target for Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) from $13 to $14. B of A Securities analyst Justin Post maintained a Neutral rating. Snap shares closed at $10.89 on Tuesday. <a href="https://www.benzinga.com/quote/SNAP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised the price target for Zebra Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) from $290 to $305. Morgan Stanley analyst Meta Marshall maintained an Underweight rating. Zebra Technologies shares closed at $384.68 on Tuesday. <a href="https://www.benzinga.com/quote/ZBRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets slashed Transcat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) price target from $130 to $110. Northland Capital Markets analyst Ted Jackson maintained a Market Perform rating. Transcat shares settled at $99.45 on Tuesday. <a href="https://www.benzinga.com/quote/TRNS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. cut Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) price target from $66 to $65. Stephens &amp; Co. analyst Jim Salera maintained an Equal-Weight rating. Chipotle shares closed at $60.49 on Tuesday. <a href="https://www.benzinga.com/quote/CMG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) price target from $220 to $175. Jefferies analyst Ashley Helgans maintained a Buy rating. e.l.f. Beauty shares closed at $113.27 on Tuesday. <a href="https://www.benzinga.com/quote/ELF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>CIBC boosted the price target for Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) from $213 to $228. CIBC analyst Kevin Chiang maintained a Neutral rating. Planet Fitness shares settled at $219.11 on Tuesday. <a href="https://www.benzinga.com/quote/WM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) price target from $80 to $96. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. PayPal shares closed at $80.28 on Tuesday. <a href="https://www.benzinga.com/quote/PYPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth MKM increased the price target for Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) from $154 to $158. Roth MKM analyst Eric Handler maintained a Neutral rating. Electronic Arts shares closed at $145.62 on Tuesday. <a href="https://www.benzinga.com/quote/EA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities boosted Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) price target from $220 to $225. Truist Securities analyst Youssef Squali maintained a Buy rating. Alphabet shares closed at $169.68 on Tuesday. <a href="https://www.benzinga.com/quote/GOOG/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GOOG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="560" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30140958/image-313-1024x560.png" alt="" class="wp-image-622467" style="width:607px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30140958/image-313-1024x560.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30140958/image-313-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30140958/image-313-768x420.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30140958/image-313.png 1215w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41599928/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-for-october">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio For October</a></li>
</ul>

News

Price Target

Markets

Trading Ideas

GOOG

GOOGL

PYPL

QRVO

SNAP

ZBRA

Alphabet To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday

Northland Capital Markets analyst Ted Jackson maintains Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) with a Market Perform and lowers the price target from $130 to $110.

Analyst Ratings

Northland Capital Markets Maintains Market Perform on Transcat, Lowers Price Target to $110

Oppenheimer analyst Martin Yang reiterates Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) with a Outperform and lowers the price target from $155 to $130.

Reiteration

Oppenheimer Reiterates Outperform on Transcat, Lowers Price Target to $130

HC Wainwright &amp; Co. analyst Scott Buck maintains Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) with a Buy and lowers the price target from $156 to $126.

HC Wainwright & Co. Maintains Buy on Transcat, Lowers Price Target to $126

Craig-Hallum analyst Greg Palm maintains Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) with a Buy and lowers the price target from $138 to $113.

Craig-Hallum Maintains Buy on Transcat, Lowers Price Target to $113

Transcat shares are trading lower after the company announced lower-than-expected Q3 financials.

HC Wainwright &amp; Co. analyst Scott Buck reiterates Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) with a Buy and maintains $156 price target.

HC Wainwright & Co. Reiterates Buy on Transcat, Maintains $156 Price Target

Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.46 by 13.04 percent. This is a 13.33 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $67.83 million which missed the analyst consensus estimate of $70.29 million by 3.51 percent. This is a 8.00 percent increase over sales of $62.80 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Transcat Q2 Adj $0.52 Beats $0.46 Estimate, Sales $67.83M Miss $70.29M Estimate

Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) will release its quarterly earnings report on Monday, 2024-10-28. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Transcat to report an earnings per share (EPS) of $0.46.
Anticipation surrounds Transcat's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.32 in the last quarter, leading to a 13.52% drop in the share price on the following day.
Here's a look at Transcat's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.36</td>
<td>0.53</td>
<td>0.35</td>
<td>0.39</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.68</td>
<td>0.66</td>
<td>0.56</td>
<td>0.60</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-14.000000000000002%</td>
<td>14.000000000000002%</td>
<td>7.000000000000001%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729879329_0.png" alt="eps graph" />
<h3>Performance of Transcat Shares</h3>
Shares of Transcat were trading at $123.46 as of October 24. Over the last 52-week period, shares are up 30.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Insights Shared by Analysts on Transcat</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Transcat.
A total of 3 analyst ratings have been received for Transcat, with the consensus rating being Buy. The average one-year price target stands at $150.0, suggesting a potential 21.5% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of MRC Global, Xometry and BlueLinx Hldgs, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Buy trajectory for MRC Global, with an average 1-year price target of $15.0, indicating a potential 87.85% downside.</li>
<li>Xometry is maintaining an Outperform status according to analysts, with an average 1-year price target of $24.5, indicating a potential 80.16% downside.</li>
<li>As per analysts' assessments, BlueLinx Hldgs is favoring an Buy trajectory, with an average 1-year price target of $136.0, suggesting a potential 10.16% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for MRC Global, Xometry and BlueLinx Hldgs, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transcat</td>
<td>Buy</td>
<td>10.08%</td>
<td>$22.66M</td>
<td>1.81%</td>
</tr>
<tr>
<td>MRC Global</td>
<td>Buy</td>
<td>-4.48%</td>
<td>$173M</td>
<td>4.72%</td>
</tr>
<tr>
<td>Xometry</td>
<td>Outperform</td>
<td>19.45%</td>
<td>$52.88M</td>
<td>-4.31%</td>
</tr>
<tr>
<td>BlueLinx Hldgs</td>
<td>Buy</td>
<td>-5.83%</td>
<td>$122.44M</td>
<td>2.20%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Transcat ranks highest in Revenue Growth among its peers. It has the lowest Gross Profit and Return on Equity compared to its peers.
<h3>About Transcat</h3>
Transcat Inc is involved in providing calibration and laboratory instrument services and distribution of test, measurement, and control instrumentation. Its product and services portfolio consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, etc. The firm has Service and Distribution operating segments. It derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Estech, FLIR, Fluke, Keysight, and Megger among others. It serves to pharmaceutical, industrial manufacturing, energy, and chemical process industries.
<h3>Financial Milestones: Transcat's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Transcat's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 10.08%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Transcat's ROE stands out, surpassing industry averages. With an impressive ROE of 1.81%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Transcat's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.44% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.08, Transcat adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/TRNS/earnings">To track all earnings releases for Transcat visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Transcat's Earnings Expectations

Craig-Hallum analyst Greg Palm maintains Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) with a Buy and lowers the price target from $150 to $138.

Craig-Hallum Maintains Buy on Transcat, Lowers Price Target to $138

4 analysts have shared their evaluations of Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $157.0, a high estimate of $160.00, and a low estimate of $156.00. Marking an increase of 11.94%, the current average surpasses the previous average price target of $140.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1722430814_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Transcat by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$156.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$156.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Martin Yang</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Scott Buck</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$156.00</td>
<td>$124.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Transcat. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Transcat compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Transcat's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Transcat's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TRNS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Transcat analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Transcat</h2>
Transcat Inc is involved in providing calibration and laboratory instrument services and distribution of test, measurement, and control instrumentation. Its product and services portfolio consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, etc. The firm has Service and Distribution operating segments. It derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Estech, FLIR, Fluke, Keysight, and Megger among others. It serves to pharmaceutical, industrial manufacturing, energy, and chemical process industries.
<h3>Transcat's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Transcat showcased positive performance, achieving a revenue growth rate of 14.25% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Transcat's net margin is impressive, surpassing industry averages. With a net margin of 9.72%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Transcat's ROE stands out, surpassing industry averages. With an impressive ROE of 3.11%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Transcat's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.42% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.1, Transcat adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Transcat Analyst Ratings

Shares of Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) fell sharply during Tuesday's session after the company reported second-quarter financial results and cut its FY24 adjusted EPS <a href="https://www.benzinga.com/general/biotech/24/07/40036607/mercks-q2-earnings-revenue-and-eps-beat-helped-by-strong-keytruda-sales-but-acquisition-costs-bit">guidance below estimates</a>.
Merck reported second-quarter sales of $16.1 billion, up 7% year-over-year, beating the consensus estimate of $15.84 billion. Excluding the impact of foreign exchange, sales increased 11%. Merck reported adjusted EPS of $2.28, a shift from an EPS loss of $(2.06), beating the consensus of $2.15, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Merck shares dipped 9.5% to $115.50 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares jumped 147.8% to $2.9250 after the company announced topline results from its Phase 2 OVATION 2 study with IMNN-001. The results showed an 11.1-month improvement in median overall survival compared to standard-of-care alone in the intent-to-treat population.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) surged 97% to $0.1731. AGAPE ATP strengthened wellness division via innovative incubation with emerging local SMEs.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares climbed 53% to $2.60 after the company announced FDA clearance of its IND application for a Phase 2 clinical trial of NGC-Cap in breast cancer.</li>
<li>INVO Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) gained 33% to $1.1513.</li>
<li>Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares gained 29% to $0.3850.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) jumped 28% to $3.4018.</li>
<li>CalciMedica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) jumped 26.3% to $5.24.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) rose 20.6% to $7.16 after the company reported better-than-expected second-quarter financial results.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) rose 19.1% to $2.3050.</li>
<li>Commvault Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) gained 19.1% to $146.77 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates. Also, the company raised its FY25 revenue guidance.</li>
<li>Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) climbed 18.8% to $13.96 after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates.</li>
<li>Meta Data Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIU#NYSE">AIU</a>) gained 18.8% to $5.42.</li>
<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) rose 18.3% to $0.59 after jumping around 6% on Monday.</li>
<li>Inspirato Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) gained 18.3% to $6.20 after jumping over 50% on Monday.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) shares gained 15.9% to $98.13 after the company reported better-than-expected second-quarter financial results and issued its third-quarter earnings guidance above estimates.</li>
<li>NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) gained 16.1% to $17.00 following upbeat earnings.</li>
<li>Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) rose 16.1% to $2.1250 after the company reported better-than-expected quarterly financial results.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) gained 15.5% to $97.79 after the company reported better-than-expected second-quarter financial results. Additionally, the company issued third-quarter earnings guidance above estimates.</li>
<li>Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) climbed 14.1% to $94.56 following better-than-expected second-quarter earnings, issued strong guidance, raised its dividend, increased its buyback authorization and issued strong guidance.</li>
<li>Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) gained 13.4% to $156.48 following -quarter earnings.</li>
<li>Varonis Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) climbed 13.3% to $54.92 as the company reported better-than-expected second-quarter financial results and raised its FY24 guidance on Monday.</li>
<li>Hayward Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) gained 11% to $14.98 after the company reported better-than-expected second-quarter EPS results.</li>
<li>F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) shares rose 10.6% to $196.46 after the company reported better-than-expected third-quarter financial results and raised its FY24 earnings guidance above estimates.</li>
<li>Pharming Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) shares gained 9.8% to $8.28. Pharming Group will report second quarter financial results on Aug. 1.</li>
<li>PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) climbed 8.5% to $63.98 after the company reported better-than-expected second quarter financial results.</li>
<li>Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) rose 8.1% to $104.28 after the company reported better-than-expected second quarter financial results. Additionally, the company revised its FY24 adjusted EPS forecast upward.</li>
<li>Gartner, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) gained 6.4% to $500.83 following better-than-expected quarterly earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares fell 80.8% to $11.44. This sudden decline was triggered by the registration of two private placements with the U.S. Securities and Exchange Commission, which unlocked millions of shares and led to increased selling pressure, Bloomberg reported on Tuesday.</li>
<li>VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) declined 64.8% to $0.1960 after the company was granted protection under Canada&#8217;s CCAA by the Ontario Superior Court. The company received approval for a DIP loan, and Ernst &amp; Young was appointed as the monitor during the restructuring process.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) dipped 40.8% to $0.6158 after the company announced it entered into an exclusive license agreement with Cortice Biosciences.</li>
<li>BIMI Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) tumbled 37% to $0.73.</li>
<li>Bloomz Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) dipped 30.7% to $1.78.</li>
<li>Ekso Bionics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) fell 26.6% to $1.0901 after the company reported worse-than-expected quarterly sales results.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares declined 25.2% to $12.27 after declining 4% on Monday.</li>
<li>VSee Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) fell 23.3% to $2.7999.</li>
<li>SmartRent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) dipped 21.5% to $1.8850 after the company announced a CEO resignation and suspended its 2024 outlook.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) shares fell 21.1% to $28.13 after the company reported worse-than-expected third-quarter earnings results and issued fourth-quarter revenue guidance below estimates.</li>
<li>Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) fell 16.5% to $152.91 after the company reported mixed third-quarter financial results and lowered its FY24 revenue guidance below estimates.</li>
<li>NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) fell 16.2% to $13.82. NIP Group announced the closing of its initial public offering and partial exercise of underwriters' option to purchase additional ADSs.</li>
<li>Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) dipped 16.2% to $43.68 after the company reported worse-than-expected quarterly financial results. Additionally, Raymond James downgraded the stock.</li>
<li>Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) shares fell 14.2% to $32.24 after the company issued roughly in-line guidance.</li>
<li>OneWater Marine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEW#NASDAQ">ONEW</a>) dipped 13.2% to $26.43 after the company reported worse-than-expected third-quarter financial results and issued weak guidance.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) shares fell 11.6% to $37.06 after reporting Phase 2 results for barzolvolimab in chronic inducible urticaria.</li>
<li>Transcat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) declined 11.2% to $120.00 following weak quarterly sales.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) dipped 9.7% to $233.65 following reports indicating Delta Air Lines would seek compensation from the cybersecurity company for last week&#8217;s outage.</li>
<li>Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) shares dipped 9.3% to $50.61 following weak quarterly sales.</li>
<li>Corning Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) fell 8.7% to $38.99 following second-quarter results.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) shares fell 8.3% to $50.40 after the company reported worse-than-expected second-quarter financial results and issued weak third-quarter revenue guidance.</li>
<li>Ecolab Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) declined 6.7% to $231.31 after the company reported worse-than-expected second-quarter sales results.</li>
<li>The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) fell 6.2% to $159.37 following a quarterly revenue miss.</li>
<li>Diageo plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>) fell 5.5% to $124.30 after the company missed annual profit expectations.</li>
<li>Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) shares declined 4.5% to $19.45 following weak quarterly sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40039797/top-3-health-care-stocks-you-may-want-to-dump-this-quarter">Top 3 Health Care Stocks You May Want To Dump This Quarter</a></li>
</ul>

Intraday Update

Movers

AMKR

ATPC

BIMI

BLMZ

CALC

CLDX

CNSP

CRWD

CVLT

EKSO

ENVB

FFIV

HAYW

HLIT

IMNN

INVO

ISPO

JBLU

JTAI

LSCC

LUMN

MBIN

NIPG

NVAX

ONEW

PCSA

PHAR

RGEN

RMBS

SMRT

TLRY

TWOU

VBIV

VRNS

VSEE

Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Transcat shares are trading lower after the company reported worse-than-expected Q1 revenue results.

Transcat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.36 by 88.89 percent. The company reported quarterly sales of $66.707 million which missed the analyst consensus estimate of $69.415 million by 3.90 percent. This is a 10.08 percent increase over sales of $60.598 million the same period last year.

Transcat Q1 2025 Adj. EPS $0.68 Beats $0.36 Estimate, Sales $66.707M Miss $69.415M Estimate

The Zacks Instruments &ndash; Control industry is likely to have benefited from the diligent focus on energy-efficient production processes and integrated software systems in the second quarter of 2024.
Industry participants, including Transcat (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trns#NASDAQ">TRNS</a>), Sensata Technologies Holding (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/st#NYSE">ST</a>) and Woodward (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wwd#NASDAQ">WWD</a>), have been benefiting from surging demand for state-of-the-art technology for replacing legacy industrial control systems with automated products.
The process instrumentation and automation industry is experiencing significant growth, primarily driven by the adoption of digital technologies like the Industrial Internet of Things in manufacturing. This trend is fueling demand for process automation, instrumentation products, safety systems and advanced sensors, which offer benefits such as improved product quality and reduced emissions. The industry&#39;s expansion is further supported by increasing regulatory requirements and the adoption of technology across various sectors.
Field instruments play a crucial role in process control by measuring key elements in industries such as chemicals, mining, and pharmaceuticals. These instruments, including transmitters for pressure, flow, temperature, level and humidity measurements, are essential for optimizing productivity. Companies with differentiated product offerings are better positioned to strengthen their market presence.
However, the industry faces challenges such as material cost inflation, rising transportation costs, and supply chain disruptions exacerbated by global events like the Russia-Ukraine conflict. These factors have impacted production schedules and profit margins as firms struggle to pass on increased costs to customers due to intense competition. The industry also contends with threats from low-cost suppliers, particularly from China, and exposure to foreign exchange fluctuations.
Despite these challenges, the industry is poised for growth, driven by increased automation adoption across sectors and investments in new technologies. North America is expected to maintain its dominant position in automation adoption, while growth in other regions is supported by infrastructural investments, evolving regulatory environments and increasing demand in various industries. The power generation, transportation, and marine sectors are also contributing to the industry&#39;s positive outlook for the second quarter of 2024.
The Instruments-Control space is housed within the broader Technology sector (one of the 16 broad Zacks sectors within the Zacks Industry classification). Per the latest Earnings Preview, the total earnings of technology companies for second-quarter 2024 are expected to be up 15.5% from the same period last year on 9.3% higher revenues.
<h3>Insight Into Key Releases</h3>
Ahead of their upcoming second-quarter 2024 earnings releases, let&#39;s take a look at the three abovementioned Instruments-Control stocks.
The Zacks model suggests that a company needs to have the right combination of two key ingredients &mdash; a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) &mdash; to increase the odds of an earnings beat.
Transcat: Increasing focus on regulatory compliance and quality assurance in healthcare, pharmaceuticals, and aerospace sectors is likely to have driven demand for Transcat&#39;s calibration services and equipment in the to-be-reported quarter. Increases in productivity, driven primarily by automation and process improvement, are expected to have boosted Service segment revenues in the quarter under review.
The company&#39;s strategic acquisitions may have expanded the company&#39;s market reach and service capabilities in the to-be-reported quarter. The acquisition of Becnel further diversifies the company&#39;s portfolio of services in regulated spaces and increases Transcat&#39;s durability. Becnel operates in a regulated environmental space with synergistic growth opportunities with large instrumentation users. Transcat continues to see growth in the higher-margin Rental business, which is benefiting from the Axiom Test Equipment acquisition. Transcat&#39;s investments in its own digital capabilities and data management solutions may be paying off in terms of operational efficiency and customer retention.
The Zacks Consensus Estimate for TRNS&#39; first-quarter fiscal 2025 earnings per share is pegged at 29 cents per share, unchanged over the past 30 days. The Zacks Consensus Estimate for total revenues is pegged at $69.06 million, suggesting 13.96% growth from the year-ago quarter.
The combination of an Earnings ESP of 0.00% and a Zacks Rank #2 makes a surprise prediction difficult. The company&#39;s earnings beat estimates in the trailing four quarters, the average surprise being 27.05%.
<div class="chart_embed">
<h3>Transcat, Inc. Price and EPS Surprise</h3>
<img alt="Transcat, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/f3/1721909336.png" style="height:300px; width:620px" title="" />
Transcat, Inc. price-eps-surprise | Transcat, Inc. Quote
Sensata Technologies: Sensata is well-positioned to gain from solid organic growth and the smooth execution of investment initiatives. Frequent product launches are aiding top-line expansion. Steady momentum in Aerospace and content growth across Automotive and Heavy vehicle off-road businesses create tailwinds. Strength in the electrification business, powered by its rich portfolio of high-voltage protection and battery management systems, propels the growth trajectory. Management noted that in the past three years, Sensata has won more than $2.3 billion in new business, with $1.3 billion gained from the electrification business.
However, the soft Sensing Solutions business, owing to a slowdown in Industrial markets, is expected to have impeded Sensata&#39;s performance in the quarter under review. For the second quarter of 2024, management expects revenues between $1.02 billion and $1.05 billion, indicating a decline of 1-3% due to foreign exchange headwinds.
The Zacks Consensus Estimate for ST&#39;s second-quarter 2024 earnings has remained unchanged at 93 cents per share in the past 30 days. For the June quarter, the Zacks Consensus Estimate for total revenues is currently pegged at $1.04 billion, suggesting a decline of 2.14% from the year-ago quarter&#39;s levels.
</div>
Sensata Technologies has an Earnings ESP of +0.15% and a Zacks Rank #3. The company&#39;s earnings outpaced estimates in three of the trailing four quarters and missed the mark once, the average surprise being 0.23%.
<div class="chart_embed">
<h3>Sensata Technologies Holding N.V. Price and EPS Surprise</h3>
<img alt="Sensata Technologies Holding N.V. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/c6/1721909221.png" style="height:304px; width:620px" title="" />
Sensata Technologies Holding N.V. price-eps-surprise | Sensata Technologies Holding N.V. Quote
Woodward: The company&#39;s performance is being driven by robust end-market demand, price realization, productivity and efficiency improvements. The Aerospace segment benefits from higher commercial OEM and commercial aftermarket sales attributed to improving passenger traffic and aircraft utilization. Defense OEM sales also improved on the back of higher ground vehicles. Defense aftermarket sales benefited from supply-chain stabilization and higher output.
Woodward&#39;s Industrial business segment is gaining from solid demand for power generation, especially in Asia and continued requirement for backup power for data centers. Higher demand for alternative fuels across the marine industry, momentum in the global marine market brought on by higher utilization, and rising shipbuilding rates are other tailwinds.
The Zacks Consensus Estimate for WWD&#39;s third-quarter fiscal 2024 earnings per share is pegged at $1.45 per share, up by a penny over the past 30 days. The Zacks Consensus Estimate for total revenues is pegged at $850.98 million, suggesting 6.28% growth from the year-ago quarter.
Woodward has an Earnings ESP of +1.73% and a Zacks Rank #3. The company&#39;s earnings beat estimates in the trailing four quarters, the average surprise being 26.09%.
</div>
<div class="chart_embed">
<h3>Woodward, Inc. Price and EPS Surprise</h3>
<img alt="Woodward, Inc. Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/48/1721909279.png" style="height:300px; width:620px" title="" />
Woodward, Inc. price-eps-surprise | Woodward, Inc. Quote
<a href="https://www.zacks.com/stock/news/2308789/can-these-3-instruments-control-stocks-beat-earnings-targets?cid=CS-BENZ-FT-analyst_blog|earnings_preview_esp-2308789">To read this article on Zacks.com click here.</a>
</div>

Small Cap

Tech

Can These 3 Instruments Control Stocks Beat Earnings Targets?

ACHR

ACVA

ALTG

CARR

CHPT

CMPR

DXPE

FBIN

FLNC

FTAI

GTEC

HUBB

ILAG

JELD

JOBY

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

RUSHA

RUSHB

SHYF

SITE

SKYX

SMXT

SNTG

TPIC

Shares of companies within the broader industrial sector are trading higher following Core Retail Sales and Retail Sales economic data. Also, strength may be due to trader optimism that the Fed will cut rates.

Transcat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) reported better-than-expected fourth-quarter financial results, after the <a href="https://www.benzinga.com/quote/TRNS/earnings">closing bell on Monday.</a>
Transcat posted adjusted earnings of 66 cents per share, beating market estimates of 53 cents per share. The company's quarterly sales came in at $70.913 million versus expectations of $68.595 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
&#8220;We are extremely pleased with our fourth quarter and full year fiscal 2024 results as double-digit organic Service revenue growth and increased productivity drove Service gross margin expansion while Distribution gross margins soared due to growth in Rentals,&#8221; commented Lee D. Rudow, President and CEO. &#8220;Adjusted EBITDA growth of 30% for the fourth quarter reflects our ability to leverage organic Service revenue growth and the successful integration of acquired companies. Fourth quarter Consolidated revenue was up 14% with gross margin expansion of 300 basis points year over year driven by our widened breadth of service offerings, excellent performance in the higher-margin rental business, and execution of automation and process improvement initiatives. Service segment revenue grew 18% in the fourth quarter as demand in highly regulated end markets, including life sciences, remained strong and our differentiated value proposition continues to resonate throughout Transcat&#8217;s expanded addressable markets.&#8221;
Transcat shares gained 2% to trade at $144.71 on Wednesday.
These analysts made changes to their price targets on Transcat after the company reported quarterly results.
<ul>
<li>HC Wainwright &amp; Co. boosted the price target on Transcat from $124 to $156. HC Wainwright &amp; Co. analyst Scott Buck maintained a Buy rating.</li>
<li>Oppenheimer increased Transcat price target from $125 to $160. Oppenheimer analyst Martin Yang maintained an Outperform rating.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38962846/jim-cramer-this-industrial-stock-is-doing-very-well-heres-his-take-on-palantir">Jim Cramer: This Industrial Stock Is Doing &#8216;Very Well&#8217;; Here&#8217;s His Take On Palantir</a>

Transcat Analysts Boost Their Forecasts After Upbeat Results

Reports Q2 revenue $67.826M, consensus $70.29M. "Consolidated revenue was up 8%. Consistent demand in our Calibration Services business was support...

Transcat reports Q2 adjusted EPS 52c, consensus 46c

In a report released today, Ted Jackson from Northland Securities reiterated a Hold rating on Transcat (TRNS – Research Report), with a price targe...

Northland Securities Reaffirms Their Hold Rating on Transcat (TRNS)

Transcat, Inc. (TRNS) Q2 2025 Earnings Call Transcript

Transcat ( ($TRNS) ) has realeased its Q2 earnings. Here is a breakdown of the information Transcat presented to its investors. Transcat, Inc. is a...

Transcat, Inc. Reports Steady Q2 Revenue and Profit Growth

H.C. Wainwright lowered the firm's price target on Transcat (TRNS) to $126 from $156 and keeps a Buy rating on the shares. The company's fiscal Q2 ...

Transcat price target lowered to $126 from $156 at H.C. Wainwright

Oppenheimer lowered the firm's price target on Transcat (TRNS) to $130 from $155 and keeps an Outperform rating on the shares. The firm notes Trans...

Transcat price target lowered to $130 from $155 at Oppenheimer

Craig-Hallum analyst Greg Palm lowered the firm's price target on Transcat (TRNS) to $113 from $138 and keeps a Buy rating on the shares. The firm ...

Transcat price target lowered to $113 from $138 at Craig-Hallum

RMT: A Micro-Cap Equity Fund For Income Investors, With A Nearly 8% Yield And 12% Discount

Warning: TRNS is at high risk of performing badly

Shares soar among industrial distributors after Trump victory

ASPN

CLBT

CLBTW

IESC

MLAB

Press Releases

Transcat Announces Third Quarter Fiscal Year 2024 Conference Call and Webcast

Transcat Reports Strong Third Quarter Results on Service Gross Margin Expansion and Adjusted EBITDA Growth

Transcat Inc. Announces Executive Leadership Changes

Transcat further expands its higher margin rental business with the acquisition of Becnel Rental Tools, Inc.

Transcat Announces Fourth Quarter Fiscal Year 2024 Conference Call and Webcast

Transcat Reports double-digit Organic Service Revenue Growth and significant Gross Margin expansion in both Segments for the Fourth Quarter and Full Year 2024

Transcat Announces First Quarter Fiscal Year 2025 Conference Call and Webcast

Transcat Reports Strong First Quarter Results with Significant Gross Margin Expansion and EBITDA Growth

Transcat Announces Second Quarter Fiscal Year 2025 Conference Call and Webcast

Transcat Reports Second Quarter Results with Growth in Revenue and Gross Profit

Alta Equipment Group Inc. Class A Common Stock

Alta Equipment Group

BioNexus Gene Lab

BlueLinx Hldgs

Euro Tech Holdings Company Limited - Ordinary Shares

Euro Tech Hldgs

Custom Truck One Source, Inc. Common Stock

Custom Truck One Source

Dnow

Distribution Solutions Group, Inc. - Common Stock

Distribution Solns Gr

DXP Enterprises

EVI Industries

FGI Industries

Global Industrial

Hudson Technologies

H&E Equipment Services, Inc. - Common Stock

H&E Equipment Servs

iPower

Karat Packaging

Lavoro

McGrath RentCorp

MRC Global

Multi Ways Holdings Limited Ordinary Shares

Multi Ways Holdings

Simpple

Titan Machinery

Willis Lease Finance Corporation - Common Stock

Willis Lease Finance

Xometry

ZKH Group Limited American Depositary Shares, each representing thirty-five (35) Class A Ordinary Shares

Comments

Transcat

Notizie

Ultime notizie per Transcat (NASDAQ:TRNS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO